Respiratory hypersensitivity reactions to NSAIDs in Europe

the global allergy and asthma network (GA(2) LEN) survey

J S Makowska, P Burney, D Jarvis, T Keil, P Tomassen, J Bislimovska, G Brozek, C Bachert, J Baelum, C Bindslev-Jensen, J Bousquet, P J Bousquet, C Kai-Håkon, S E Dahlen, B Dahlen, W J Fokkens, B Forsberg, M Gjomarkaj, P Howarth, E Salagean & 14 andre C Janson, L Kasper, U Kraemer, C Louiro, B Lundback, J Minov, E Nizankowska-Mogilnicka, N Papadopoulos, A G Sakellariou, A Todo-Bom, E Toskala, J E Zejda, T Zuberbier, M L Kowalski

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.

METHODS: The GA(2) LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15-74 from their general population, and in three centers (Athens, Munich, Oslo), a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by mail. Totally, 62 737 participants completed the questionnaires.

RESULTS: The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%), and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%), and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.

CONCLUSION: Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors.

OriginalsprogEngelsk
TidsskriftAllergy
Vol/bind71
Udgave nummer11
Sider (fra-til)1603-1611
ISSN0105-4538
DOI
StatusUdgivet - 2016

Fingeraftryk

Respiratory Hypersensitivity
Hypersensitivity
Pharmaceutical Preparations
Drug Hypersensitivity
Population
Postal Service
Respiratory System
Surveys and Questionnaires
Multivariate Analysis
Smoking
Odds Ratio

Citer dette

Makowska, J. S., Burney, P., Jarvis, D., Keil, T., Tomassen, P., Bislimovska, J., ... Kowalski, M. L. (2016). Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA(2) LEN) survey. Allergy, 71(11), 1603-1611. https://doi.org/10.1111/all.12941
Makowska, J S ; Burney, P ; Jarvis, D ; Keil, T ; Tomassen, P ; Bislimovska, J ; Brozek, G ; Bachert, C ; Baelum, J ; Bindslev-Jensen, C ; Bousquet, J ; Bousquet, P J ; Kai-Håkon, C ; Dahlen, S E ; Dahlen, B ; Fokkens, W J ; Forsberg, B ; Gjomarkaj, M ; Howarth, P ; Salagean, E ; Janson, C ; Kasper, L ; Kraemer, U ; Louiro, C ; Lundback, B ; Minov, J ; Nizankowska-Mogilnicka, E ; Papadopoulos, N ; Sakellariou, A G ; Todo-Bom, A ; Toskala, E ; Zejda, J E ; Zuberbier, T ; Kowalski, M L. / Respiratory hypersensitivity reactions to NSAIDs in Europe : the global allergy and asthma network (GA(2) LEN) survey. I: Allergy. 2016 ; Bind 71, Nr. 11. s. 1603-1611.
@article{92905162b47d4c09b6fc703beb9789d7,
title = "Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA(2) LEN) survey",
abstract = "BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.METHODS: The GA(2) LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15-74 from their general population, and in three centers (Athens, Munich, Oslo), a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by mail. Totally, 62 737 participants completed the questionnaires.RESULTS: The mean prevalence of NSAID-induced dyspnea was 1.9{\%} and was highest in the three Polish centers [Katowice (4.9{\%}), Krakow (4.8{\%}), and Lodz (4.4{\%})] and lowest in Skopje, (0.9{\%}), Amsterdam (1.1{\%}), and Umea (1.2{\%}). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95{\%}CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.CONCLUSION: Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors.",
author = "Makowska, {J S} and P Burney and D Jarvis and T Keil and P Tomassen and J Bislimovska and G Brozek and C Bachert and J Baelum and C Bindslev-Jensen and J Bousquet and Bousquet, {P J} and C Kai-H{\aa}kon and Dahlen, {S E} and B Dahlen and Fokkens, {W J} and B Forsberg and M Gjomarkaj and P Howarth and E Salagean and C Janson and L Kasper and U Kraemer and C Louiro and B Lundback and J Minov and E Nizankowska-Mogilnicka and N Papadopoulos and Sakellariou, {A G} and A Todo-Bom and E Toskala and Zejda, {J E} and T Zuberbier and Kowalski, {M L}",
note = "{\circledC} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2016",
doi = "10.1111/all.12941",
language = "English",
volume = "71",
pages = "1603--1611",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Online",
number = "11",

}

Makowska, JS, Burney, P, Jarvis, D, Keil, T, Tomassen, P, Bislimovska, J, Brozek, G, Bachert, C, Baelum, J, Bindslev-Jensen, C, Bousquet, J, Bousquet, PJ, Kai-Håkon, C, Dahlen, SE, Dahlen, B, Fokkens, WJ, Forsberg, B, Gjomarkaj, M, Howarth, P, Salagean, E, Janson, C, Kasper, L, Kraemer, U, Louiro, C, Lundback, B, Minov, J, Nizankowska-Mogilnicka, E, Papadopoulos, N, Sakellariou, AG, Todo-Bom, A, Toskala, E, Zejda, JE, Zuberbier, T & Kowalski, ML 2016, 'Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA(2) LEN) survey', Allergy, bind 71, nr. 11, s. 1603-1611. https://doi.org/10.1111/all.12941

Respiratory hypersensitivity reactions to NSAIDs in Europe : the global allergy and asthma network (GA(2) LEN) survey. / Makowska, J S; Burney, P; Jarvis, D; Keil, T; Tomassen, P; Bislimovska, J; Brozek, G; Bachert, C; Baelum, J; Bindslev-Jensen, C; Bousquet, J; Bousquet, P J; Kai-Håkon, C; Dahlen, S E; Dahlen, B; Fokkens, W J; Forsberg, B; Gjomarkaj, M; Howarth, P; Salagean, E; Janson, C; Kasper, L; Kraemer, U; Louiro, C; Lundback, B; Minov, J; Nizankowska-Mogilnicka, E; Papadopoulos, N; Sakellariou, A G; Todo-Bom, A; Toskala, E; Zejda, J E; Zuberbier, T; Kowalski, M L.

I: Allergy, Bind 71, Nr. 11, 2016, s. 1603-1611.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Respiratory hypersensitivity reactions to NSAIDs in Europe

T2 - the global allergy and asthma network (GA(2) LEN) survey

AU - Makowska, J S

AU - Burney, P

AU - Jarvis, D

AU - Keil, T

AU - Tomassen, P

AU - Bislimovska, J

AU - Brozek, G

AU - Bachert, C

AU - Baelum, J

AU - Bindslev-Jensen, C

AU - Bousquet, J

AU - Bousquet, P J

AU - Kai-Håkon, C

AU - Dahlen, S E

AU - Dahlen, B

AU - Fokkens, W J

AU - Forsberg, B

AU - Gjomarkaj, M

AU - Howarth, P

AU - Salagean, E

AU - Janson, C

AU - Kasper, L

AU - Kraemer, U

AU - Louiro, C

AU - Lundback, B

AU - Minov, J

AU - Nizankowska-Mogilnicka, E

AU - Papadopoulos, N

AU - Sakellariou, A G

AU - Todo-Bom, A

AU - Toskala, E

AU - Zejda, J E

AU - Zuberbier, T

AU - Kowalski, M L

N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.METHODS: The GA(2) LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15-74 from their general population, and in three centers (Athens, Munich, Oslo), a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by mail. Totally, 62 737 participants completed the questionnaires.RESULTS: The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%), and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%), and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.CONCLUSION: Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors.

AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAID-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.METHODS: The GA(2) LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15-74 from their general population, and in three centers (Athens, Munich, Oslo), a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of NSAID-induced hypersensitivity reactions were sent to participants by mail. Totally, 62 737 participants completed the questionnaires.RESULTS: The mean prevalence of NSAID-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%), and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%), and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.CONCLUSION: Our study documented significant variation between European countries in the prevalence of NSAID-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors.

U2 - 10.1111/all.12941

DO - 10.1111/all.12941

M3 - Journal article

VL - 71

SP - 1603

EP - 1611

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 11

ER -